Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

received an ossein-hydroxyapatite complex

Phase 3Small molecule

UUniversity of Opole

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

TraumatologyRecruiting

TraumatologyPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

Traumatology

NCT07210281

Clinical

Trials by Indication[1]

Traumatology1 trial

Osteogenon in Orthopedics and Traumatology

Recruiting·UUniversity of Opole·Phase 4·NCT07210281·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for received an ossein-hydroxyapatite complex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — received an ossein-hydroxyapatite complex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for received an ossein-hydroxyapatite complex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Opole company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Opole

Related News